Rapamycin, through the blockade of cytokine release and the inhibition of a microglia immune response, has been shown to reduce clinical symptomatology and inflammatory responses in models of experimental autoimmune encephalomyelitis [134]; it has been suggested that inhibition of mTOR pathways may be necessary to reduce the risk of MS development [135]. The gene discussed is MTOR; the disease is myeloid sarcoma.